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This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and 
Lasmiditan target the trigeminovascular system and respectively, are characterized in the 
gepant and ditan classes of pharmaceuticals. Based on a review of studies, Rimegepant was 
determined to be the advantageous acute treatment. This is not conclusive due to inequivalent 
comparison in sample size and amount of research completed. It is encouraged for additional 
research to be imposed before a conclusive determination of the advantageous acute 
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MIGRAINE PRIMARY HEADACHE OVERVIEW 
Introduction to Primary Headaches 
The research of primary headache disorders elicits several limitations due to being frequently 
diagnosed with inadequate pathogenesis comprehension. The primary headaches can be 
distinguished into four categories including tension type headaches, migraines, trigeminal 
autonomic cephalalgias, and other primary headache disorders1 2. In epidemiological studies, 
the number of diseased cases within a population is measured by the prevalence. The global 
prevalence for primary headaches is approximately 50%3 4, however several regions of the 
world are not included in this average due to the lack of available data5. Reiterating the 
limitations exhibited in primary headache research, geographical gaps hinder an accurate 
quantification of individuals afflicted globally4 6. Nonetheless, when comparing published 
reputable studies, tension type headaches and migraines were found to be the most globally 
recurring. Tension type headache episodes are described to be bilateral obtaining a mild to 
moderate intensity. They are characterized into chronic and episodic; chronic lasting greater 
than 15 days and episodic lasting from a few hours up to a few days7. Episodic can further be 
subdivided into infrequent and frequent categories, with the latter requiring 10 episodes 
minimal between the time-span of 1-14 days/ month2. Contrastingly, migraines are 
distinguished into aura and without aura classifications – both recurrent lasting 4-72 hours. As 
defined in the International Classification of Headache Disorders (ICHD), migraines without 
aura are indicative of a unilateral location, pulsating quality, moderate or severe intensity, 
nausea and/or photophobia and phonophobia2.  Migraines with aura are similarly unilateral, 
but obtain visual, sensory, or other central nervous system symptoms that are reversible2 8. 
Discriminating between migraines and tension type headaches is often difficult within a 
clinical setting due to simultaneous occurrence of attacks in patients who get headaches 
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frequently. Due to this, a recent development of more specific criteria was established by the 
ICHD for differentiation of the phenotypic resemblance of migraines and tension type 
headaches exhibited in some patients2. This additional criterion allows for diagnosis precision 
in the health care setting, thus improving clinical research as well. 
A retrospective systemic study was conducted by the Global Burden of Disease in 2016 
estimating the prevalence of tension type headaches at 30.8% and migraines at 18.9%5. 
According to this study, although the tension type headaches are more prevalent, migraines 
have a larger implication of disease burden. A disease burden can be quantified because it is 
directly proportional to disability weights. Disability weights are defined as the disabling 
consequence and it is measured by the percentage of health lost during an attack, in 
comparison to a person with full health. Globally, the disease weight for migraines are 
significantly greater. They estimate to be around 43.4%, while the disease weight for tension 
type headaches are around 3.7%5. With migraines obtaining such a high degree of burden 
followed by a high prevalence, there is a significant need in migraine research development 
for pharmacological advancements. Conflict is induced because migraine primary headaches 
are independent of underlying medical conditions and lack causative pathology9. By 
determining causative pathology, more drugs can be developed directly targeting the source of 
affliction, thus resulting in reduced burden amongst populations. Various implications 
regarding migraine pathology have been the focal point of many studies for this goal, but 
despite advances in research the genesis remains unknown. There has been lethargic 
progression of innovative migraine medications to aid in the control of disease burden and 
temporarily eradicate pain. New medications have emerged targeting the potential inflicted 
origin of migraines for acute medicinal purposes. The purpose of this research aims to 
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evaluate two contemporary medications that may be primitive in decreased affliction 
worldwide. A brief overview of hypotheses that represent the premise of migraine 
pharmacology will be included in order to better elucidate the mechanistic actions of the new 
medications. Rimegepant and Lasmiditan target the trigeminovascular system, characterizing 
within the gepant and ditan classes of pharmaceuticals, respectively. Their mechanisms of 
attack within the trigeminovascular system will be contrasted. The advantageous acute 




AN OVERVIEW OF PROPOSED MIGRAINE HYPOTHESIS 
Although pathogenesis of migraines are unknown, neurological changes exhibited during migraine 
attacks have assisted tremendously in the development of potential drug targets. Historically, a 
proposed hypothesis by Thomas Willis indicated that migraine etiology solely involved the 
vasodilation of arterioles, which led to development of the vascular theory10. Based on 
experimentation the vascular theory is credible in some regard, but it can be refuted. Drugs inducing 
vasoconstriction are quite effective in treatment. Contrastingly, drugs inducing cranial vasodilation, 
such as nitroglycerine, have been shown to cause hypersensitivity to noxious somatosensory 
stimulation11. Although vasodilation and hypoperfusion of blood flow does occur within migraines, 
evidence shows this is not the primitive reason for affliction. In fact, vasoactive intestinal peptide 
(VIP) is a transmitter that imposes cranial vasodilation, but there is evidence of migraines not 
triggered as a result of intravenous VIP infusion12 13. Regardless, it can be stated that vasodilation is a 
part of a migraine triggering cascade that causes an increase in the release of neuropeptides promoting 
neurogenic inflammation and noxious stimulation.  
Trigeminovascular system in migraines 
The neuropeptide release and resulting inflammation that typically appears during a migraine attack is 
a focal point in generation of drug targets. The mechanistic action leading to the release of 
neuropeptides remain debatable and unknown. Many hypotheses focus on different mechanistic 
pathways involved with Dural vasculature and the trigeminovascular system. The discovery by Ray 
and Wolff in 1940 showed that electrical and mechanical stimulation of the dura mater generated 
pain14. The dura mater of the meninges is where the bulk of meningeal afferents are located, 
innervated with nociceptors. This coincides with the early work completed by Ray and Wolff, 
because nociceptors encode for noxious stimuli. It is stated that a triggering event sensitizes and 
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activates trigeminal nociception, while releasing several neuropeptides that promote neurogenic 
inflammation and vasodilation. Triggering stimuli such as stress, fatigue, not eating on time, 
environmental stimuli, and hormonal changes may be indicative of generating this response15 16 13 17. 
The cell bodies of the meningeal afferents are within the trigeminal ganglion. The transmitted 
information from the meningeal afferent axons are delivered primarily through the ophthalmic branch 
of the trigeminal nerve, but a small amount of information is transmitted through the mandibular and 
maxillary branches as well16. From here, it is stated that the trigeminal nerve conveys sensory 
information from intracranial structures, and there is apparent evidence that extracranial structure 
sensory information is conveyed as well18. Using electrophysiological techniques with rats as the 
model organism, several studies indicated that pericranial tissues are effected in noxious stimulation19 
20. In continuance with the pathway, information is then delivered into the spinal trigeminal nucleus 
for relay. The spinal trigeminal nucleus can be subdivided into three distinct parts, with each relaying 
a different sensory modality. The subnucleus paralis and subnucleus interparalis both relay 
discriminative tactile information of the trigeminal nerve, while the subnucleus caudalis is 
responsible for pain and temperature21. Figure 1 provides a depiction of this process. This theory is a 
plausible explanation for migraine occurrence but does not account for additional stimulation that 
occurs in other neuronal anatomical features. Not only this, but evidence shows various other 
physiological changes that occur during migraines are pertinent to the type (aura and without aura). 
This further introduces supplemental proposed hypotheses.  
Hypothalamus and Brainstem Activation in Migraine 
Hypothalamic and brainstem nuclei activation is a significant physiological occurrence during 
spontaneous migraine attack. Substantial evidence shows the involvement of persistent activation and 
increased blood flow to the hypothalamus and brainstem using positron emission tomography22 23 24. 
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A study conducted with animal models indicated that there is direct control on spontaneity of the 
spinal trigeminal nucleus via the paraventricular hypothalamic nucleus25. Similarly, brainstem nuclei 
activation is correlated with migraine because it is proposed to result in either the enhancement or 
inhibition of neurons facilitating  trigeminovascular pain transmission in the spinal and medullary 
dorsal horn26 27 28. The mechanism of action for the modulation of the brainstem to migraines is 
unspecific, despite occurrence being prevalent during attack. Within Figure 1, the link between 
hypothalamic and brainstem activation to the trigeminovascular system is evident. 
Mast Cell Degranulation in Migraine 
A diverged hypothesis from Dural and trigeminovasculature innervation involves the mast cells 
which are proliferated around the meningeal afferents in the dura mater. A trigger response may 
degranulate the mast cells to release pro-inflammatory mediators leading to the release of sensory 
peptides from meningeal nociceptors13 16. There are two considerations when discussing mast cell 
degeneration. Some state that mast cell degeneration results from neuropeptide release from 
meningeal afferents13 26. However, there are implications that mast cells can initiate nociceptor 
sensitizing neuropeptide release16. Migraines can be triggered by hormonal input, and mast cell 
degranulation occurs in response to the binding these hormonal peptides to the expressed 
progesterone and estrogen receptors on their surface16. Figure 2 provides a depiction of both 
pathways. This research is not conclusive, but the degranulation of mast cells in migraine allow it to 
be a potential target in migraine pharmacology. 
Aura Physiological Changes in Migraine 
As stated earlier, migraine without aura are characterized by photophobia and phonophobia. Evidence 
has showed a slight increase in blood flow within the brainstem regions and the visual and cingulate 
auditory cortices29. Interestingly, there seems to be an affiliation with the brainstem increased 
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perfusion of blood in aura migraine attacks as well30. A discrepancy that is distinctive to migraine 
aura attacks is a physiological process entitled cortical spreading depression (CSD). Cortical 
spreading depression is depicted by a disruption of electrical activity across the cortical grey matter 
surface of the brain, resulting in suppressed neural activity29 31. This disruption is characterized by 
high extracellular potassium concentration and influx of sodium and chloride. It is linked to migraine 
with aura because it slowly propagates within the primary visual cortex, generating a retinotopic 
visual percept32. Evidence also shows that CSD can be a triggering factor for activation and 
sensitization of the trigeminovascular system, thus inducing neurogenic inflammation13. Research 
remains pertinent regarding the mechanism for CSD. It has been implied that sensitization of the 
blood brain barrier results from CSD30, and increases the brain’s sensitivity to neuropeptides in order 
to trigger migraines. This has been refuted by experimentation, but the speculation of CSD causing 
sensitization remains.  
Neuropeptide Secretion in Migraine 
An association of all the variant proposed migraine triggering cascades is the increased release of 
vasoactive neuropeptides at nerve endings. The release is dependent on the type of nerve fiber that 
innervates the dura vasculature. Parasympathetic and sympathetic nerve fibers are innervated 
throughout the dura resulting in the potential release of various neuropeptides. The parasympathetic 
fibers typically release vasoactive intestinal peptide, Neuropeptide Y, Acetylcholine, and nitric oxide 
synthase. The sympathetic fibers of the dura stimulate the release of norepinephrine, neuropeptide Y, 
as well as ATP33. Trigeminal sensory nerves typically release the neuropeptides calcitonin gene-
related peptide (CGRP), Neurokinin A, Pituitary adenylate cyclase-activating peptide (PACAP), 
nitric oxide synthase, and substance P which coexists in the nerve terminal with serotonin (5-HT)34. 
Serotonin is not only located within these nerve terminals, but it is interspersed throughout the 
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trigeminovascular system35. The serotonin neurotransmitter is assumed to play a role in migraine due 
to an altered concentration during an attack. The mechanism of action and high or low concentration 
amount remains debatable. Historically, high levels of 5-hydroxyindoleacetic (a serotonin precursor) 
was found in the urine36 which was presumed to equate to lower abundance of serotonin in the brain. 
Low serotonin levels have also been linked to intensifying sensory processing information such as the 
primary auditory cortex36. Contrastingly, other research proves that the plasma levels of the serotonin 
precursor does not affect the abundance of serotonin in the brain. Recently, a study was published that 
tracked serotonin levels indirectly using positron emission tomography. A serotonin receptor (5-HT4) 
was radiolabeled and could be quantified as inversely proportional to the serotonin levels. The results 
hypothesized that high levels of serotonin are possibly a result or trait of migraine37. The various 
hypotheses imposed on serotonin levels in migraine elicits the importance of continued migraine 
research. Serotonergic receptors are successful drug targets for mitigating pain. Stronger targets 
directly impacting serotonin concentration can be developed when the physiological effects and 
mechanisms are concluded. See Table 1 for the neurotransmitters released correspondent to the nerve 
fiber as listed above.
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A NEW APPROACH TO ACUTE MIGRAINE PHARMACOLOGY 
Impact of Development  
Acute migraine treatment is sufficient for short term relief with patients who experience 
recurrent migraines lasting within the range of 4-72 hours for short term relief. This treatment 
is typically effective in migraines with aura and without aura. A commonly used over the 
counter medication are nonsteroidal anti-inflammatory drugs (NSAIDS). As stated earlier, 
neurogenic inflammation is a characteristic occurrence during a migraine attack. Upon 
inflammation, prostaglandin secretion is implied to elicit sensitization of nociceptors in the 
brain38. Cyclooxygenase is the enzyme responsible for the conversion of arachidonic acid into 
prostaglandins, which stimulate pain generation and inflammation. Based on experimentation, 
both cyclooxygenase 1 and 2 can be found in the dura of the meninges38. The inhibition of 
Cyclooxygenase via NSAIDs can prevent the cascade of nociceptor activation and pain. 
NSAIDs are only utilized if the patient attains a mild to moderate intensity migraine39, 
therefore other acute migraine treatments should be used for those in which NSAIDs are 
rendered ineffective. Commonly used stronger migraine medications include ergot derivatives 
and triptans. These are non-specific 5-HT1D/1B agonists obtaining a slight amount of selectivity 
to the 5-HT1F receptor. These agonists play a role in vasoconstriction of arterioles
35. Due to 
this vasoconstriction property of triptans and ergot derivatives, inflicted individuals with 
cardiovascular problems are eliminated from use. The development of specific drugs would 
thus make mitigation of migraine accessible to all. Rimegepant and Lasmiditan, were recently 
developed to manage the degree of affliction worldwide. See Table 2 for a depicted 




As stated in the preceding sections, neuropeptide release is a key component in migraine 
occurrence due to promotion of neurogenic inflammation and noxious stimulation. CGRP is a 
proinflammatory vasodilator that is released from trigeminal nerve fibers to bind to CGRP 
receptors. There is an additional CGRP binding receptor entitled AMY1 that is imposed to 
have an similar binding strength as the CGRP receptor, given they are in the same family40 41 
42. AMY1 is classified as an adrenomedullary receptor, and all receptors in this class are 
capable of binding CGRP. The gepant classification of pharmaceuticals is characterized by 
antagonistic properties towards the CGRP receptor, which should eliminate the activation of 
the migraine triggering cascade. Gepants are preferable alternatives to acute migraine 
treatment due to the lack of vasoconstrictive properties that the triptans and ergot derivatives 
attain. Conflict arose when the clinical development of gepants was temporarily halted due to 
liver toxicity upon exposure43. Evidence coincides with the liver toxicity resulting from 
development of a potential metabolite byproduct of the drug, so a new drug creation was 
necessary that rid this property. The ensuing development was Rimegepant – recently 
approved by the FDA in February 202044.  
Mechanism of Action 
The exact mechanism for Rimegepant binding is unknown, but like other gepants, it is an 
antagonist to the CGRP receptor (see Figure 3). A recent study was conducted and stated 
Rimegepant obtained an affinity to the CGRP receptor 65 times higher than the 
adrenomedullin receptors40. They indicated that if AMY1 and additional adrenomedullin 
receptors played a role in the CGRP activation cascade with equivalence, Rimegepant would 
not be effective. However, this can be refuted. A recent in vitro study within Cos7 transfected 
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cells was conducted, which tested the ability of Rimegepant to antagonize against AMY1 and 
additional adrenomedullin receptors45. This study elucidated that binding occurred to both 
receptors. Because the study did not take place in human subjects or animal models, a vast 
amount of limitations is prevalent when analyzing. Additional experimentation should be 
completed for a better understanding of Rimegepant targeting and mechanism of action. 
Evaluation of Studies 
Several studies were completed measuring the safety and efficacy of Rimegepant (75 mg oral 
tablet administered) in migraine treatment by utilizing various methods. One 12-week study 
estimated the safety of Rimegepant as a preventative treatment by simultaneously 
administering monoclonal antibodies. There were 16 patients that were screened for the study, 
but only 13 began treatment, and only a total completion of 10. It was stated that two of the 
participants who dropped the study gave no indication of why, but the remaining participant 
elicited lack of efficacy for the drug. Of the 13 individuals that began treatment, the average 
age of all patients was approximately 49.9 years with 11/13 women participants46. The 
participants had to be afflicted with at least 2-8 migraines per month in order to be involved 
with the study. Three different types of monoclonal antibodies were used, and the patients 
were given the medication for approximately 4 weeks. It was concluded that this combination 
was safe and more effective than singular monoclonal antibody use. One of the major 
limitations of this study was the small sample size. A small sample size is not generalizable, 
therefore additional experimentation should be done before normalizing concomitant use of 
Rimegepant and monoclonal antibodies as a migraine prevention method. 
A larger study included 1186 individuals with the intent being to measure the efficacy of 
Rimegepant solely. The study was not measured overtime, but rather in a single occurrence, 
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and was also double-blind. This implies that some individuals received the Rimegepant, while 
others received a placebo. The administers nor participants could distinguish the difference 
between the two samples. In order to participate in the study, all participants had to have a 
history of migraine that occurred about 2-8 times per month for at least a year. The number of 
individuals no longer experiencing pain after oral ingestion of Rimegepant was measured after 
a time frame of two hours (indicated relief period). The demographics of the participants were 
predominantly female and an average age of 40.6 years old. Upon attack, patients recorded 
answers to questions in an electronic diary which pertained to the undergoing symptoms, 
bothersome features during attack like nausea, phonophobia, and photophobia, as well as 
ratings pertinent to the intensity of pain47. The results indicated that approximately 19.6% of 
the patients who received the Rimegepant experienced relief of pain and 12.0% that received 
the placebo experienced relief of pain. Also, results showed that approximately of patients 
who took Rimegepant had a 37.6% of diminished bothersome symptoms after 2 hours. This 
was significantly higher than the placebo that was administered which had a 25.2% 
bothersome symptom relief. There were many limitations within this study, but a major 
limitation was frequency of recorded data. Earlier, I established how the study was not based 
overtime, but on one occurrence. There is a lack of credibility because measurement overtime 
allows for consistency or inconsistency of the results to be determined. 
Adverse Effects 
The adverse effects caused by Rimegepant use differed for both studies enlisted above. When 
patients simultaneously used monoclonal antibodies and Rimegepant, 2 out of 13 individuals 
experienced nasopharyngitis which was rendered a normal adverse effect. Others experienced 
back pain, dizziness, sinusitis, myalgia, contusion, and a first-degree AV block46. These 
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effects were individualized – only inflicting one patient. The AV block could have possibly 
been associated with the treatment, which is a plausible downside given that Rimegepant was 
created to be a more universally used drug in comparison to the triptans. Due to the small 
sample size, generalized conclusions cannot be made, further advocating for more research. 
When analyzing the study that screened 1811 participants, cardiovascular adverse effects were 
not prevalent. However, it is important to note that subjects who obtained cardiovascular 
disease were eliminated from the study, therefore conclusion upon adverse cardiac effects on 
inflicted patients cannot be determined. The significant effects with a 1% incidence greater 
than placebo included nausea and urinary tract infections. 
Lasmiditan 
Mechanism of Action 
Lasmiditan was developed October of 201948 in efforts to target migraines more selectively in 
comparison to triptans and ergot derivatives. Categorized in the ditan class of 
pharmaceuticals, Lasmiditan aims to act as an agonist towards the 5-HT1F receptor to prevent 
the occurrence of neurogenic inflammation within the migraine triggering cascade49 (see 
Figure 4). Lasmiditan was determined to be a quite effective treatment that could be 
universally applicable to patients due to the lack of vasoconstriction properties that triptans 
and ergot derivatives obtain. When discussing the effects of the 5-HTF receptor within the 
trigeminovascular system, there is indication that it acts centrally and peripherally35. This is 
primarily due to the location of the receptors being in both the trigeminal ganglion, as well as 
the nucleus caudalis. Additional details of Lasmiditan discuss its implicated effects throughout 
the cascade. Due to the agonistic effects of 5-HTF, CGRP release can possibly be inhibited 
along with other neurotransmitters. 
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Evaluation of Studies 
To determine the efficacy of treatment with and without concomitant prevention methods, a 
double-blind study was conducted including 3981 participants. Three different doses of 
Lasmiditan (50 mg, 100 mg, or 200 mg) and a placebo was administered to participants 
randomly. The criteria applicable was each participant had to be afflicted with 3-8 migraines 
per month and had to be over the age of 18. The mean age of participants was 45.7 years, and 
primarily women were involved in the study. In order to analyze efficacy, patients received an 
electronic journal in which they answered questions pertaining to the pain they experienced 
throughout attack, burden imposed due to attack, and effectiveness after the medication. The 
results elicited that patients experienced significant effectiveness when taking Lasmiditan 
compared to the placebo51. 698 of 3981 patients were established to use prevention 
medications if they were taking beta blockers, epileptic medications, and anti-depressants for 
a total of three months. The results did not establish a statistical significance between 
concomitant use and sole use, proving the compound is effective without the addition of a 
preventative treatment. A major limitation of this study was that although two trials were 
completed, only one utilized the 50 mg Lasmiditan dosage. This adds a lack of consistency 
within the study. 
Another study completed determined the safety and efficacy of Lasmiditan amongst 
individuals who obtain cardiovascular risk factors52. Approximately 77.9% of the participants 
had at least one cardiovascular risk. The criteria were similar to the study described above. It 
consisted of individuals who were afflicted with 3-8 migraines per month and at least 18 years 
of age. Lasmiditan dosage at 100 mg and 200 mg, along with a placebo was randomly given 
to 1856 participants and data was analyzed via an electronic diary 2 hours post medication 
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ingestion. The results indicated that 32.2% of patients were free of migraine pain after 
Lasmiditan and 15.3% were free after placebo. The most bothersome symptom was also 
quantified with participants having 40.7% relief after ingesting the Lasmiditan and 29.5% of 
individuals experiencing relief after ingesting the placebo. A limitation within this study was 
that there was only a comparison of Lasmiditan with 100 mg and 200 mg in patients with 
cardiovascular risk. The effect of cardiovascular risk on a 50 mg Lasmiditan tablet was not 
deduced, which could have further proved effectiveness.  
Adverse Effects 
The adverse effects included in each Lasmiditan study were not unexpected. The first study 
had effects of dizziness, paresthesia, somnolence, fatigue, nausea, muscle weakness and 
hypoesthesia. The rates for individuals taking preventative medications were very similar. The 
other study had effects of dizziness, paresthesia, somnolence, fatigue, hypoesthesia, nausea, 
and lethargy. The incidence was higher than 2% in every Lasmiditan group for these effects, 
and greater than the placebo group52. This study also included the incidence of cardiovascular 
anomalies. These cardiovascular effects were quite low in comparison, comprising of 




























It is evident that increased research is crucial to determine migraine pathogenesis for 
production direct targeting medications. However, the acute treatments discussed do not 
provide pain relief to all patients. As stated earlier, prophylactic treatments include the usage 
of monoclonal antibodies when discussing CGRP antagonists. Monoclonal antibodies have 
shown to be effective towards patients with medically intractable migraines53. Additionally, a 
recent advancement has showed that neuromodulation has been very effective towards 
patients who are resistant to the migraine acute treatments discussed. Neuromodulation is a 
technique in which there is imposed electrical stimulation on various anatomical structures. 
The stimulated areas that have proven to be effective for intractable migraines include the 
occipital nerve, vagus nerve, sphenopalatine ganglion, supraorbital nerve, transcutaneous 
vagus, and transcranial magnetic stimulation54. These techniques provided are conducive to 
the subset of patients who experience contraindications and resistance to acute treatments. 
All the Rimegepant and Lasmiditan studies evaluated in this research were quite similar and 
were promising in terms of effectiveness and safety. However, a lot of unknowns are 
prevalent. The full mechanistic action of Rimegepant is unknown, and studies linking 
effectiveness towards cardiovascular patients have not yet been demonstrated. Similarly, the 
complete mechanistic action of Lasmiditan is unknown, and various adverse effects are 
presumable based on the evaluated studies. When reviewing the concomitant use of 
Rimegepant with preventative treatment (monoclonal antibodies), it was proposed 
Rimegepant increased efficacy. When reviewing the concomitant use of Lasmiditan with 
preventative treatments (beta blockers, epileptic medications, and anti-depressants), the 
efficacy was not increased and remained the same. Additionally, in the second Lasmiditan 
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study evaluated, the adverse effects included dizziness, paresthesia, somnolence, fatigue, 
hypoesthesia, nausea, and lethargy. Not only this, but these adverse effects obtained an 
incidence of greater than 2% when comparing to the placebo. In comparison, the double-
blind study of Rimegepant indicated only nausea and urinary tract infections as the adverse 
effects with an incidence higher than 1% compared to the placebo. Based on these results, it 
can be stated that Rimegepant is the advantageous acute treatment. This is not conclusive due 
to several limitations regarding fair comparisons. When comparing drugs, prices can have a 
huge effect on whether they are deemed more advantageous or not. Comparing two drugs 
elicits individualized perspectives. The sample sizes are not equivalent, which can account 
for a misnomer in adverse effects. There has yet to be a study showing the cardiovascular 
effects of Rimegepant upon at risk participants which can cause additional adverse effects 
that are not yet established. Also, very little clinical trials on Rimegepant are developed due 
to its recent approval. Therefore, it is encouraged for additional research to be imposed 





Based on the results established in this study, Rimegepant appears to be the advantageous acute treatment. 
This is not conclusive due to inequivalent comparison in sample size and amount of research completed. It 
is encouraged for additional research to be imposed before a conclusive determination of the advantageous 
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